Progenitor Cell Therapy in Dilative Cardiomyopathy
30 participantsStarted 2004-05
Plain-language summary
Intracoronary infusion of bone marrow derived progenitor cells into the LAD in patients with non ischemic dilated cardiomyopathy.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age 8-80
* Dilated Cardiomyopathy, Ejection fraction \< 40%
* LVEDD \> 60mm
* Stable clinical condition within last 6 months
* Written informed consent
Exclusion Criteria:
* Myocardial infarction or coronary intervention in the past
* Change of medical therapy within the last 6 weeks prior to cell therapy
* Tumor within last 5 years or incomplete remission
* Active infection
* Active bleeding
* Stroke within last 2 years
* Surgery or trauma within last 2 months
* Uncontrolled hypertension
* HIV infection
* Chronic inflammatory disease
* Liver disease (GOT \> 2x upper normal limit)
* Renal dysfunction (creatinin \> 2.0mg/dl)
* Thrombopenia \< 100.000
* Anemia (hemoglobin \< 8.5 g/dl)
* Mental retardation
What they're measuring
1
LV function (Ejection fraction within 3 months) Simpson